Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for OS Therapies Incorporated (OSTX : AMEX)

• Company Description    OS Therapies Incorporated is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors. The company's lead asset consists OST-HER2. OS Therapies Incorporated is based in NEW YORK. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $1.67 Daily Weekly Monthly 20 Day Moving Average: 702,221 shares Shares Outstanding: 28.10 (millions) Market Capitalization: $46.92 (millions) Beta: 52 Week High: $6.48 52 Week Low: $1.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.24% -12.64% 12 Week 9.15% -8.19% Year To Date -60.98% -63.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15825 SHADY GROVE ROAD SUITE 135 - ROCKVILLE,MD 20850 USA ph: 410-297-7793 fax: - ostx@redchip.com http://www.ostherapies.com

• General Corporate Information    Officers Paul A.Romness - Founder; Chairman; President and Chief Executive O Christopher P.Acevedo - Chief Financial Officer John Ciccio - Director Avril McKean Dieser - Director Karim Galzahr - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68764Y207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 28.10 Most Recent Split Date: (:1) Beta: Market Capitalization: $46.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.54 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 25.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -344.83 12/31/24 - -358.61 Current Ratio 06/30/25 - - 03/31/25 - 1.16 12/31/24 - 1.20 Quick Ratio 06/30/25 - - 03/31/25 - 1.16 12/31/24 - 1.20 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.19 12/31/24 - -0.24 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©